MX2020005707A - Profarmacos de creatina, composiciones y metodos de uso de estos. - Google Patents
Profarmacos de creatina, composiciones y metodos de uso de estos.Info
- Publication number
- MX2020005707A MX2020005707A MX2020005707A MX2020005707A MX2020005707A MX 2020005707 A MX2020005707 A MX 2020005707A MX 2020005707 A MX2020005707 A MX 2020005707A MX 2020005707 A MX2020005707 A MX 2020005707A MX 2020005707 A MX2020005707 A MX 2020005707A
- Authority
- MX
- Mexico
- Prior art keywords
- compositions
- methods
- creatine
- creatine prodrugs
- prodrugs
- Prior art date
Links
- CVSVTCORWBXHQV-UHFFFAOYSA-N creatine Chemical compound NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 title abstract 6
- 229960003624 creatine Drugs 0.000 title abstract 3
- 239000006046 creatine Substances 0.000 title abstract 3
- 239000000203 mixture Substances 0.000 title abstract 2
- 229940002612 prodrug Drugs 0.000 title abstract 2
- 239000000651 prodrug Substances 0.000 title abstract 2
- 230000007812 deficiency Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/001—Acyclic or carbocyclic compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/002—Heterocyclic compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
- C07C279/20—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups containing any of the groups, X being a hetero atom, Y being any atom, e.g. acylguanidines
- C07C279/22—Y being a hydrogen or a carbon atom, e.g. benzoylguanidines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
- C07D213/82—Amides; Imides in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D273/00—Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups C07D261/00 - C07D271/00
- C07D273/02—Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups C07D261/00 - C07D271/00 having two nitrogen atoms and only one oxygen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
- C07D317/10—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings
- C07D317/32—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D317/34—Oxygen atoms
- C07D317/40—Vinylene carbonate; Substituted vinylene carbonates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Medicinal Preparation (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762593731P | 2017-12-01 | 2017-12-01 | |
| PCT/US2018/063580 WO2019109067A2 (en) | 2017-12-01 | 2018-12-03 | Creatine prodrugs, compositions and methods of use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2020005707A true MX2020005707A (es) | 2020-08-20 |
Family
ID=66665277
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020005707A MX2020005707A (es) | 2017-12-01 | 2018-12-03 | Profarmacos de creatina, composiciones y metodos de uso de estos. |
Country Status (14)
| Country | Link |
|---|---|
| US (3) | US11332438B2 (https=) |
| EP (1) | EP3717453A4 (https=) |
| JP (2) | JP7433226B2 (https=) |
| KR (1) | KR102678696B1 (https=) |
| CN (1) | CN111417620B (https=) |
| AR (1) | AR118403A1 (https=) |
| AU (1) | AU2018375199B2 (https=) |
| BR (1) | BR112020010805B1 (https=) |
| CO (1) | CO2020006542A2 (https=) |
| IL (1) | IL274701B2 (https=) |
| MX (1) | MX2020005707A (https=) |
| SG (1) | SG11202004336VA (https=) |
| TW (1) | TWI815832B (https=) |
| WO (1) | WO2019109067A2 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102678696B1 (ko) * | 2017-12-01 | 2024-06-27 | 울트라제닉스 파마수티컬 인코포레이티드 | 크레아틴 전구약물, 조성물과 이의 사용 방법 |
| US11383694B1 (en) | 2021-08-13 | 2022-07-12 | Oshkosh Defense, Llc | Electrified military vehicle |
| WO2024136952A1 (en) * | 2022-12-20 | 2024-06-27 | Florida Atlantic University Board Of Trustees | Phosphagen system modulators and uses thereof |
| US20250017886A1 (en) * | 2023-07-06 | 2025-01-16 | Vireo Systems, Inc. | Formulations and methods for increasing creatinine levels in plasma, extracellular fluid and/or intracellular compartments |
Family Cites Families (76)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0718000B2 (ja) | 1985-05-15 | 1995-03-01 | 日本真空技術株式会社 | 合成樹脂被膜の形成方法 |
| US4767627A (en) | 1985-05-29 | 1988-08-30 | Merck & Co., Inc. | Drug delivery device which can be retained in the stomach for a controlled period of time |
| US4915952A (en) | 1987-02-27 | 1990-04-10 | Alza Corporation | Composition comprising drug, HPC, HPMC and PEO |
| US4786503A (en) | 1987-04-06 | 1988-11-22 | Alza Corporation | Dosage form comprising parallel lamine |
| US5002772A (en) | 1988-05-31 | 1991-03-26 | Pfizer Inc. | Gastric retention system for controlled drug release |
| CA1340821C (en) | 1988-10-06 | 1999-11-16 | Nobuyuki Fukazawa | Heterocyclic compounds and anticancer-drug reinforcing agents containing them as effective components |
| US5007790A (en) | 1989-04-11 | 1991-04-16 | Depomed Systems, Inc. | Sustained-release oral drug dosage form |
| EP0595894B1 (en) | 1991-07-19 | 1995-12-20 | UNIROYAL CHEMICAL COMPANY, Inc. | Seed film compositions |
| US6235313B1 (en) | 1992-04-24 | 2001-05-22 | Brown University Research Foundation | Bioadhesive microspheres and their use as drug delivery and imaging systems |
| US5643909A (en) | 1993-04-19 | 1997-07-01 | Syntex (U.S.A.) Inc. | 10,11-Methanodibenzosuberane derivatives |
| JPH0718000A (ja) * | 1993-06-18 | 1995-01-20 | Takeda Chem Ind Ltd | 新規ペプチド |
| US5451409A (en) | 1993-11-22 | 1995-09-19 | Rencher; William F. | Sustained release matrix system using hydroxyethyl cellulose and hydroxypropyl cellulose polymer blends |
| AU4151996A (en) | 1994-11-08 | 1996-05-31 | Avicena Group, Inc. | Use of creatine or creatine analogs for the treatment of diseases of the nervous system |
| US5945125A (en) | 1995-02-28 | 1999-08-31 | Temple University | Controlled release tablet |
| MY113429A (en) | 1995-02-28 | 2002-02-28 | Univ Temple | Controlled release tablet containing swellable polyethylene oxide |
| US5824638A (en) | 1995-05-22 | 1998-10-20 | Shire Laboratories, Inc. | Oral insulin delivery |
| AU721190B2 (en) | 1995-10-11 | 2000-06-29 | Avicena Group, Inc. | Use of creatine analogues for the treatment of disorders of glucose metabolism |
| US5783212A (en) | 1996-02-02 | 1998-07-21 | Temple University--of the Commonwealth System of Higher Education | Controlled release drug delivery system |
| IT1282650B1 (it) | 1996-02-19 | 1998-03-31 | Jagotec Ag | Compressa farmaceutica,caratterizzata da elevato aumento di volume a contatto con liquidi biologici |
| US6008252A (en) | 1996-07-26 | 1999-12-28 | Beale; Paxton K. | Method for increasing muscle mass in a mammal |
| US6210710B1 (en) | 1997-04-28 | 2001-04-03 | Hercules Incorporated | Sustained release polymer blend for pharmaceutical applications |
| GB9710699D0 (en) | 1997-05-24 | 1997-07-16 | Danbiosyst Uk | Gastro-retentive controlled release system |
| US6635280B2 (en) | 1997-06-06 | 2003-10-21 | Depomed, Inc. | Extending the duration of drug release within the stomach during the fed mode |
| PT1003476E (pt) | 1997-08-11 | 2005-05-31 | Alza Corp | Forma de dosagem de agente activo de libertacao prolongada adaptada para retencao gastrica |
| US6090411A (en) | 1998-03-09 | 2000-07-18 | Temple University | Monolithic tablet for controlled drug release |
| US6797283B1 (en) | 1998-12-23 | 2004-09-28 | Alza Corporation | Gastric retention dosage form having multiple layers |
| US6476006B2 (en) | 2000-06-23 | 2002-11-05 | Teva Pharmaceutical Industries, Ltd. | Composition and dosage form for delayed gastric release of alendronate and/or other bis-phosphonates |
| US20030008007A1 (en) | 2001-04-23 | 2003-01-09 | Jose Gutierrez-Rocca | Release pharmaceutical construct for gastric retention |
| US20030013767A1 (en) | 2001-07-13 | 2003-01-16 | Samuel Bessman | Method of treating weight loss using creatine |
| US20040219186A1 (en) | 2001-08-16 | 2004-11-04 | Ayres James W. | Expandable gastric retention device |
| US7125568B2 (en) | 2001-08-23 | 2006-10-24 | Sung Michael T | Lipophilic drug compositions |
| US6723340B2 (en) | 2001-10-25 | 2004-04-20 | Depomed, Inc. | Optimal polymer mixtures for gastric retentive tablets |
| AU2002363998A1 (en) | 2001-12-15 | 2003-06-30 | Spherics, Inc. | Bioadhesive drug delivery system with enhanced gastric retention |
| EP1478345A4 (en) | 2002-01-03 | 2010-11-17 | Glaxosmithkline Llc | NOVEL PHARMACEUTICAL DOSAGE FORMS AND PROCESS FOR PRODUCTION OF SAID DOSAGE FORMS |
| DE10221344A1 (de) | 2002-05-14 | 2003-12-04 | Hannover Med Hochschule | Transgene Ratte und ihre Verwendung im Tiermodell für die humane Chorea Huntington Erkrankung sowie Nukleinsäurekonstrukte, Vektoren und Zellen zu ihrer Erzeugung |
| MXPA04011325A (es) * | 2002-05-16 | 2005-02-14 | Bayer Cropscience Gmbh | Derivados de piridina-carboxamida y su uso como plaguicidas. |
| BR0310100A (pt) | 2002-05-17 | 2007-04-27 | Esperion Therapeutics Inc | métodos para tratar, prevenir ou reduzir a lesão de reperfusão isquêmica em um tecido ou órgão, e para prevenir ou tratar de uma condição associada com a privação de oxigênio, seguida por suprimento de oxigênio aumentado a um tecido ou órgão em necessidade disto |
| US20040102525A1 (en) | 2002-05-22 | 2004-05-27 | Kozachuk Walter E. | Compositions and methods of treating neurological disease and providing neuroprotection |
| US20040126366A1 (en) | 2002-06-04 | 2004-07-01 | Rima Kaddurah-Daouk | Methods of treating cognitive dysfunction by modulating brain energy metabolism |
| GB0214013D0 (en) | 2002-06-18 | 2002-07-31 | Euro Celtique Sa | Pharmaceutical product |
| WO2004002445A2 (en) | 2002-06-26 | 2004-01-08 | Cadila Healthcare Limited | Novel floating dosage form |
| US20040120983A1 (en) | 2002-12-23 | 2004-06-24 | Philip Connolly | Nutritional supplement |
| JPWO2005108370A1 (ja) | 2004-04-16 | 2008-03-21 | 味の素株式会社 | ベンゼン化合物 |
| US8106093B2 (en) | 2004-07-02 | 2012-01-31 | Baylor Research Institute | Glycogen or polysaccharide storage disease treatment method |
| US20060046962A1 (en) | 2004-08-25 | 2006-03-02 | Aegis Therapeutics Llc | Absorption enhancers for drug administration |
| US20060045865A1 (en) | 2004-08-27 | 2006-03-02 | Spherics, Inc. | Controlled regional oral delivery |
| US20080103202A1 (en) | 2004-11-08 | 2008-05-01 | Chris Ferguson | Method of preparing creatine ester salts and uses thereof. |
| US20070012105A1 (en) | 2005-07-13 | 2007-01-18 | Barnes-Jewish Hospital | Method and apparatus for resistive characteristic assessment |
| US20070032750A1 (en) | 2005-07-15 | 2007-02-08 | Jeffrey Oster | Muscle strength assessment system |
| US7683043B2 (en) | 2006-06-06 | 2010-03-23 | Xenoport, Inc. | Creatine phosphate analog prodrugs, compositions and uses thereof |
| WO2007146085A2 (en) | 2006-06-06 | 2007-12-21 | Xenoport, Inc. | Creatine phosphate prodrugs, compositions and uses thereof |
| US20070281995A1 (en) | 2006-06-06 | 2007-12-06 | Xenoport, Inc. | Creatine analog prodrugs, compositions and uses thereof |
| AU2007332800A1 (en) | 2006-12-07 | 2008-06-19 | Avicena Group, Inc. | Creatine compositions for skin treatment |
| US7319157B1 (en) | 2007-02-20 | 2008-01-15 | Multi Formulations Ltd. | Creatine-fatty acids |
| WO2008101310A1 (en) | 2007-02-20 | 2008-08-28 | Multi Formulations Ltd. | Creatine-fatty acids |
| WO2008101309A1 (en) | 2007-02-20 | 2008-08-28 | Multi Formulations Ltd. | Creatine-fatty acids |
| US8426395B2 (en) | 2008-05-30 | 2013-04-23 | Northern Northern Innovations Holding Corp | Preparations containing creatine and imino sugars |
| WO2010005692A2 (en) | 2008-06-16 | 2010-01-14 | E. I. Du Pont De Nemours And Company | Insecticidal cyclic carbonyl amidines |
| WO2010074591A1 (ru) | 2008-12-24 | 2010-07-01 | Закрытое Акционерное Общество "Beptekc" | Амиды креатина, способ их получения, средство, обладающее нейропротекторным действием |
| CA2785714C (en) | 2009-12-30 | 2016-01-26 | Baylor Research Institute | Anaplerotic therapy for alzheimer's disease and the aging brain |
| CN103079555A (zh) | 2010-06-14 | 2013-05-01 | 贝勒研究院 | 用于成人葡萄糖多聚体病（apbd）治疗的三庚酸甘油酯膳食 |
| JP5702248B2 (ja) * | 2011-07-28 | 2015-04-15 | 三菱製紙株式会社 | ナノファイバー、ナノファイバーの形成方法およびナノファイバー集合体の形成方法 |
| HK1200459A1 (en) | 2011-09-19 | 2015-08-07 | Gencia Corporation | Modified creatine compounds |
| US9233099B2 (en) | 2012-01-11 | 2016-01-12 | University Of Cincinnati | Methods of treating cognitive dysfunction by modulating brain energy metabolism |
| AR091857A1 (es) | 2012-07-25 | 2015-03-04 | Sova Pharmaceuticals Inc | INHIBIDORES DE CISTATIONIN-g-LIASA (CSE) |
| EP2692719B1 (en) | 2012-07-30 | 2016-06-08 | Commissariat à l'Énergie Atomique et aux Énergies Alternatives | Method for preparing creatine fatty esters, creatine fatty esters thus prepared and uses thereof |
| ITTO20121098A1 (it) | 2012-12-18 | 2014-06-19 | Univ Degli Studi Genova | Procedimento per sintetizzare derivati della creatina |
| JP6689199B2 (ja) * | 2013-08-30 | 2020-04-28 | モーメンティブ・パフォーマンス・マテリアルズ・インク | アミノ酸を含む湿気硬化性化合物 |
| US20160289175A1 (en) * | 2013-11-05 | 2016-10-06 | Ultragenyx Pharmaceutical Inc. | Creatine analogs and the use thereof |
| ITTO20131070A1 (it) | 2013-12-24 | 2015-06-25 | Univ Degli Studi Genova | Applicazione terapeutica di un derivato di creatina |
| US9642825B2 (en) | 2014-02-27 | 2017-05-09 | 4141 Holdings, Llc | Bio-available N-acetyl creatine species and compositions thereof |
| EP3194370A4 (en) | 2014-09-03 | 2018-01-24 | Lumos Pharma, Inc. | Synthesis of cyclocreatine and analogs thereof |
| US9617230B2 (en) | 2014-12-22 | 2017-04-11 | Farmington Pharma Development | Creatine prodrugs, compositions and methods of use thereof |
| WO2016110822A1 (en) * | 2015-01-09 | 2016-07-14 | Universita' Degli Studi Di Genova | Carboxylic biacyl creatine derivative, uses and method of synthesis thereof |
| US11021501B2 (en) | 2015-03-30 | 2021-06-01 | Farmington Pharma Development | Creatine phosphate analog prodrugs, compositions and methods of use thereof |
| KR102678696B1 (ko) | 2017-12-01 | 2024-06-27 | 울트라제닉스 파마수티컬 인코포레이티드 | 크레아틴 전구약물, 조성물과 이의 사용 방법 |
-
2018
- 2018-12-03 KR KR1020207018932A patent/KR102678696B1/ko active Active
- 2018-12-03 MX MX2020005707A patent/MX2020005707A/es unknown
- 2018-12-03 SG SG11202004336VA patent/SG11202004336VA/en unknown
- 2018-12-03 AU AU2018375199A patent/AU2018375199B2/en active Active
- 2018-12-03 BR BR112020010805-7A patent/BR112020010805B1/pt active IP Right Grant
- 2018-12-03 JP JP2020527818A patent/JP7433226B2/ja active Active
- 2018-12-03 AR ARP180103527A patent/AR118403A1/es unknown
- 2018-12-03 WO PCT/US2018/063580 patent/WO2019109067A2/en not_active Ceased
- 2018-12-03 US US16/764,969 patent/US11332438B2/en active Active
- 2018-12-03 IL IL274701A patent/IL274701B2/en unknown
- 2018-12-03 CN CN201880077165.5A patent/CN111417620B/zh active Active
- 2018-12-03 TW TW107143208A patent/TWI815832B/zh active
- 2018-12-03 EP EP18883842.9A patent/EP3717453A4/en active Pending
-
2020
- 2020-05-28 CO CONC2020/0006542A patent/CO2020006542A2/es unknown
-
2022
- 2022-03-28 US US17/706,283 patent/US11753369B2/en active Active
-
2023
- 2023-07-14 US US18/352,959 patent/US20240092731A1/en active Pending
- 2023-09-20 JP JP2023152930A patent/JP7542705B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| AR118403A1 (es) | 2021-10-06 |
| SG11202004336VA (en) | 2020-06-29 |
| JP2024009811A (ja) | 2024-01-23 |
| AU2018375199A1 (en) | 2020-05-28 |
| BR112020010805A2 (pt) | 2020-11-10 |
| CN111417620A (zh) | 2020-07-14 |
| IL274701A (en) | 2020-06-30 |
| TWI815832B (zh) | 2023-09-21 |
| US20240092731A1 (en) | 2024-03-21 |
| CO2020006542A2 (es) | 2020-06-09 |
| JP2021505537A (ja) | 2021-02-18 |
| CA3082184A1 (en) | 2019-06-06 |
| IL274701B1 (en) | 2024-03-01 |
| WO2019109067A2 (en) | 2019-06-06 |
| WO2019109067A3 (en) | 2020-03-26 |
| US11332438B2 (en) | 2022-05-17 |
| BR112020010805B1 (pt) | 2024-01-30 |
| EP3717453A4 (en) | 2021-07-28 |
| JP7433226B2 (ja) | 2024-02-19 |
| US11753369B2 (en) | 2023-09-12 |
| US20220227703A1 (en) | 2022-07-21 |
| IL274701B2 (en) | 2024-07-01 |
| AU2018375199B2 (en) | 2023-03-30 |
| EP3717453A2 (en) | 2020-10-07 |
| TW201927368A (zh) | 2019-07-16 |
| US20210002211A1 (en) | 2021-01-07 |
| JP7542705B2 (ja) | 2024-08-30 |
| KR102678696B1 (ko) | 2024-06-27 |
| KR20200105833A (ko) | 2020-09-09 |
| CN111417620B (zh) | 2023-08-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MY205416A (en) | Tyk2 inhibitors and uses thereof | |
| MX394380B (es) | Compuestos dinucleótidos cíclicos para eltratamiento de cáncer | |
| EP3848370A3 (en) | Tyk2 inhibitors and uses thereof | |
| EP4327809A3 (en) | Tyk2 inhibitors and uses thereof | |
| GEP20247593B (en) | Compositions and methods of inhibiting masp-3 for the treatment of various diseases and disorders | |
| CL2016003422A1 (es) | Inhibidores de demetilasa-1 específico de lisina | |
| MX2018003472A (es) | Moduladores de la expresion de kras. | |
| TN2017000544A1 (en) | 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2-yl carbamate derivatives as magl inhibitors | |
| TN2019000211A1 (en) | Antitumoral compounds | |
| PH12017501057A1 (en) | Substituted 2-anilinopyrimidine derivatives as egfr modulators | |
| CL2016003423A1 (es) | Inhibidores de demetilasa-1 específico de lisina | |
| MX2018006632A (es) | Inhibidores biciclicos de peptidilarginina deiminasa 4 (pad4). | |
| SG10201809518QA (en) | Processes of preparing a jak1 inhibitor and new forms thereto | |
| MX2017011997A (es) | Carbamatos de piperacina y metodos de preparacion y uso. | |
| SG10201909805XA (en) | Surface modified polymer compositions | |
| SA520411187B1 (ar) | نظائر فينيل ألانينول كربامويل واستخداماتها | |
| EP4650000A3 (en) | High concentration formulation | |
| PH12017501539A1 (en) | Disacetoxytubulysin h and analogs thereof | |
| AU2015299431B2 (en) | Pyrrolidinone derivatives as metAP-2 inhibitors | |
| PH12016501751A1 (en) | Pyridazine derivatives for use in the prevention or treatment of an ataxic disorder | |
| JOP20190163B1 (ar) | منشط nrf2 | |
| PH12017500459A1 (en) | Azetidinyloxyphenylpyrrolidine compounds | |
| MX2020005707A (es) | Profarmacos de creatina, composiciones y metodos de uso de estos. | |
| MX382092B (es) | Compuestos heterocíclicos para el tratamiento de enfermedades. | |
| PH12018501943A1 (en) | Pharmaceutical compositions for the treatment of cancer |